VIP236 not checked

Vincerx Pharma, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.”In the company’s words, NCT05712889 on ClinicalTrials.gov
Tested for
Neoplasms
Main trialPhase 1
“Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer”In the company’s words, NCT05712889 on ClinicalTrials.gov

Other drugs for Neoplasms

All 2440 drugs for Neoplasms

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 10 Oct 2024 Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow VIP236

Following is part of Solo: you see every change to VIP236 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in